ClinicalTrials.gg
CompletedNCT03533283Updated Nov 2, 2026

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

A Phase 1/2 interventional study of Glofitamab and Atezolizumab in Non-Hodgkins Lymphoma, sponsored by Hoffmann-La Roche. Completed at 20 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

How we know · 14 judgments

Updated Nov 2, 2026Now CompletedFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
211
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche — 1 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Non-Hodgkin · Hoffmann-La Roche.

Enrollment
16th of 49
211 · median 121
Started
2018
with 2 others
Phase 1/2
13 of 54
none open now
Registered
46th of 54
by date

Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 16th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2018, is one of 13 in phase 1/2, and was the 46th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

1 of the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult patients.

This study includes an additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin's lymphoma to image CD8+T-cells at baseline and after treatment with glofitamab, including pre-treatment with obinutuzumab.

03

Conditions studied

  • Non-Hodgkins Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Main Inclusion Criteria

  • -confirmed hematologic that is expected to express CD20 ( after or refractory to respond to at least one prior treatment regimen; no available treatment options that are expected to prolong survival or patients refusing chemotherapy or stem cell transplant (SCT))
  • Dose-escalation: Grades 1-3b relapsed or refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL) (nodal; extra-nodal; or splenic), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL) with MYC and BCL2 and/or BCL6 rearrangements (double-hit lymphoma), HGBCL not otherwise specified (NOS), DLBCL arising from FL (transformed FL)
  • Dose-expansion: R/R LBCL, including DLBCL NOS, DLBCL arising from FL (transformed FL), PMBCL, HGBCL with MYC and BCL2 and/or BCL6 rearrangements (i.e., double-hit and triple-hit lymphomas), and HGBCL NOS
  • At least one measurable target lesion
  • Fresh pre-treatment , but if this cannot be taken, a previous archived biopsy from lesion can be taken as replacement if it is not older than 6 months and not confounded by major events (progression, treatment)
  • (ECOG) performance status of 0-2
  • Adequate organ function (liver, hematological, renal)
  • Negative test results for virus (HBV), virus (HCV), and (HIV)

Inclusion criteria

Inclusion Criteria Specific to Imaging Substudy

  • At least two measurable target lesions
  • Able to provide two fresh tumor biopsies (baseline and on-treatment)

Main Exclusion Criteria

  • Participants with Chronic Lymphocytic Leukemia (CLL), acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma, Richter's transformation, CD20-positive ALL, Burkitt lymphoma, or lymphoplasmacytic lymphoma
  • Current > Grade 1 peripheral neuropathy (only for participants being treated in the polatuzumab vedotin arm)
  • Patients with known active infection, or reactivation of a latent infection within 4 weeks prior to Obinutuzumab (Gpt) infusion
  • Patient with history of confirmed progressive multifocal leukoencephalopathy (PML)
  • History of
  • Current or past history of central nervous system (CNS) lymphoma
  • Current or past history of CNS disease
  • Major surgery or significant traumatic injury \</=28 days prior to Gpt infusion
  • Significant cardiovascular disease or significant pulmonary disease
  • Active or history of disease or immune deficiency (with exceptions, e.g. hypothyroidism and Diabetes mellitus Type 1)
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Treatment with any other standard anti-cancer radiotherapy / chemotherapy including therapy within 4 weeks prior to Gpt infusion
  • Prior solid organ transplantation
  • Prior allogenic stem cell transplant (SCT)
  • Autologous SCT within 100 days prior to Gpt infusion
  • Documented refractoriness to an obinutuzumab-monotherapy regimen
  • Prior treatment with anti-cancer/lymphoma therapies and systemic immunotherapeutic/immunostimulating agents within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to Gpt infusion
  • Any history of immune related >/= Grade 3 adverse events (AE) with the exception of endocrinopathy managed with replacement therapy
  • Ongoing use >25 milligrams/day of prednisone or equivalent within 4 weeks prior to and during study treatment
  • Treatment with systemic medication
  • Administration of a live, attenuated vaccine within 4 weeks prior to Gpt infusion or anticipation that such a will be required during the study or within 5 months after last dose of study treatment

Exclusion criteria

Exclusion Criteria Specific to Imaging Substudy

  • Circulating lymphoma cells, defined by out of range (high) absolute lymphocyte count and/or the presence of abnormal/malignant cells in the peripheral blood differential signifying circulating lymphoma cell
  • Participants who have had splenectomy or functional asplenia that could compromise protocol objectives
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    Atezolizumab

    Participants will receive Glofitamab in combination with Atezolizumab up to the maximum tolerated dose (MTD).

    Drug: Glofitamab · Drug: Atezolizumab · Drug: Obinutuzumab · Drug: Tocilizumab

  • Experimental
    Polatuzumab Vedotin

    Participants will receive Glofitamab in combination with polatuzumab vedotin up to the MTD.

    Drug: Glofitamab · Drug: Obinutuzumab · Drug: Tocilizumab · Drug: Polatuzumab Vedotin

  • Experimental
    Imaging Sub-study

    Participants will undergo positive-emission tomography/computed tomography (PET/CT) at screening, followed by an "Imaging Cycle," to replace Cycle 1 of the main study. Eligible participants will have the option roll-over to the atezolizumab arm of the main study from Cycle 2 onwards.

    Drug: Glofitamab · Drug: Obinutuzumab · Drug: 89Zr-Df-IAB22M2C

Interventions

  • Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.

    Also known as: RO7082859, Columvi

  • Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).

  • Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.

  • Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).

    Also known as: Actemra

  • Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).

  • DrugZirconium Zr 89 Crefmirlimab BerdoxamStudies of Zirconium Zr 89 Crefmirlimab BerdoxamZirconium Zr 89 Crefmirlimab Berdoxam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.

06

What researchers measure

Primary outcomes

  1. Best Objective Response Rate (ORR) as Measured by Independent Review Committee (IRC)

    Time frame: Baseline until the end of treatment (13 to 14 months), then ever 3 months until end of study visit (to occur within 4 weeks of disease progression)

  2. Dose Limiting Toxicities (DLTs)

    Time frame: Atezolizumab Arm: During DLT period of 21 days (or up to 42 days in the case of cycle delay), starting on Day 1, Cycle 2; Polatuzumab Vedotin Arm: During 5-week DLT period starting Cycle 1, Day 8

Secondary outcomes

  1. Best ORR as Measured by Investigator

    Time frame: Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)

  2. Best Complete Response (CR) Rate, as Assessed by Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) Scan

    Time frame: Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)

  3. Duration of Complete Response (DOCR)

    Time frame: Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)

  4. Duration of Response (DOR)

    Time frame: Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)

  5. Progression-Free Survival (PFS)

    Time frame: Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)

  6. Event-Free Survival (EFS)

    Time frame: Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)

  7. Time to First Complete Response (TFCR)

    Time frame: Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)

  8. Time to First Overall Response (TFOR)

    Time frame: Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)

  9. Overall Survival (OS)

    Time frame: Baseline through end of survival follow-up phase (survival follow-up is every 3 months until death, lost to follow-up, withdrawal of consent, or study termination)

  10. Percentage of Participants with Adverse Events (AEs)

    Time frame: Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)

  11. Incidence and Severity of Cytokine Release Syndrome (CRS) Following Glofitamab Administration

    Time frame: Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)

  12. Anti-Drug Antibody (ADA) Formation

    Time frame: Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)

  13. Elimination Half-Life (T1/2) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin

    Time frame: At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)

  14. Area Under the Concentration-Time Curve (AUC) for Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin

    Time frame: At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)

  15. Time to Maximum Observed Serum Concentration (Tmax) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin

    Time frame: At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)

  16. Maximum Observed Serum Concentration (Cmax) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin

    Time frame: At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)

  17. Minimum Serum Concentration (Cmin) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin

    Time frame: At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)

  18. Clearance (CL) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin

    Time frame: At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)

  19. Volume of Distribution at Steady-State (Vss) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin

    Time frame: At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)

  20. CD8-Positive T Cell Proliferation

    Time frame: At pre-defined intervals during the study treatment period (up to 17 cycles; Cycle = 21 days)

  21. CD20-Positive B-Cell Reduction

    Time frame: At pre-defined intervals during the study treatment period (up to 17 cycles; Cycle = 21 days)

  22. SUVmax of 89Zr-Df-IAB22M2C (Imaging Sub-study)

    Time frame: From baseline to Day 13

  23. SUVpeak of 89Zr-Df-IAB22M2C (Imaging Sub-study

    Time frame: From baseline to Day 13

  24. SUVmean of 89Zr-Df-IAB22M2C (Imaging Sub-study)

    Time frame: From baseline to Day 13

  25. Tumor Volume Based on 89Zr-Df-IAB22M2C PET-uptake (Imaging Sub-study)

    Time frame: From baseline to Day 13

  26. Quantitation of CD8+ Cells on Biopsy Samples (Imaging Sub-study)

    Time frame: From baseline to Day 13

07

Study locations

20 sites
  • Novant Health Cancer Institute
    Charlotte, North Carolina 28204, United States
  • UZ Gent
    Ghent, 9000, Belgium
  • Aarhus Universitetshospital Skejby
    Aarhus N, 8200, Denmark
  • Rigshospitalet
    København Ø, 2100, Denmark
  • Odense Universitetshospital
    Odense C, 5000, Denmark
  • Hadassah Ein Karem Hospital
    Jerusalem, 9112001, Israel
  • Rabin Medical Center-Beilinson Campus
    Petah Tikva, 4941492, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Istituto Nazionale Tumori Irccs Fondazione g. Pascale
    Naples, Campania 80131, Italy
  • Policlinico S.Orsola-Malpighi
    Bologna, Emilia-Romagna 40138, Italy
  • Asst Papa Giovanni Xxiii
    Bergamo, Lombardy 24127, Italy
  • Fond. IRCCS Istituto Nazionale Tumori
    Milan, Lombardy 20133, Italy
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Duran i Reynals
    Barcelona, 08907, Spain
  • START Madrid-FJD, Hospital Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Clinico Universitario Virgen de la Victoria
    Málaga, 29010, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • The HOPE Clinical Trials Unit
    Leicester, LE1 5WW, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, W1T 7HA, United Kingdom
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, NE1 4LP, United Kingdom
08

References and documents

Publications

  • Hutchings M, Sureda A, Bosch F, Larsen TS, Corradini P, Avigdor A, Terol MJ, Dominguez AR, Pinto A, Skarbnik A, Cordoba R, Jorgensen JM, Zinzani PL, Leung W, Bottos A, Li D, Relf J, Tandon M, Sellam G, Gritti G. Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. J Clin Oncol. 2025 Dec 20;43(36):3788-3798. doi: 10.1200/JCO-25-00992. Epub 2025 Oct 20. PubMed 41115257 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Oct 2026, 101 months.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's 101 months is above that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2018
First posted
May 23, 2018
StartActual
May 8, 2018
Primary completionActual
Oct 22, 2026
CompletionActual
Oct 22, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 2, 2026
Sites
1 site added — first site in United States
Show site
  • Novant Health Cancer Institute · Charlotte, United States
Oct 2, 2026
Primary completion
Oct 16, 2026→Oct 22, 2026 (actual)
Nov 2, 2026
Study completion
Oct 16, 2026→Oct 22, 2026 (actual)
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Active, not recruiting→Completed
    Primary completion Oct 16, 2026→Oct 22, 2026 (now actual)
    Study completion Oct 16, 2026→Oct 22, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 2, 2026
    1 site added — first site in United States
    Show site
    • Novant Health Cancer Institute · Charlotte, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03533283
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 23, 2018
Start date
May 8, 2018
Primary completion
Oct 22, 2026
Completion
Oct 22, 2026
Last update
Nov 2, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Polatuzumab vedotin

Start the discussion